DATA GRAPHICS | Data Byte
Plus: Approvals in earlier cancer lines for Rybrevant and Opdivo, and new indications for four more products
By Gunjan Ohri, Data Content Analyst
April 27, 2024 12:10 AM UTC


Highlights among FDA’s supplemental approvals in March include conversions of accelerated approvals for two drugs, and label expansions to earlier treatment lines or new indications for half a dozen products.
After receiving accelerated approval in November 2022, FDA granted Elahere mirvetuximab soravtansine, an FOLR1 antibody-drug conjugate from AbbVie Inc. (NYSE:ABBV), full approval based on the results of the confirmatory Phase III MIRASOL trial. In the study, which compared Elahere with chemotherapy in platinum-resistant ovarian cancer patients who had received three prior therapies, Elahere led to a median overall survival of 16.46 months vs. 12.75 months (HR=0.67; p=0.0046). …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652238/fda-label-expansions-march-brought-full-approvals-of-elahere-rybrevant